In collaboration with other rheumatology departments nationwide randomized controlled trials in early rheumatoid arthritis have been carried out. The typical design is a 1-2 year RCT-study, which is followed by an open cohort study. A central clinical database, an imaging database, and a biobank are established.
CIMESTRA: MTX + cyclosporine versus MTX + placebo with results published up to year 10 on long-term effect of early aggressive treatment, prognostic values of biomarkers and new insight into the pathogenesis has been assessed.
OPERA: MTX + adalimumab versus MTX + placebo. Year 1 data show 20% improvement in remission.
DanAct Early: MTX + tocilizumab versus MTX + placebo in early rheumatoid arthritis analysis ongoing.
In these studies the participants include the majority of the Danish rheumatology departments. A steering commitee is established for conducting the studies.
DANBIO (the nationwide register for treatment with biological) is used for trials in chronic rheumatoid arthritis.
About the region
Hospitals located in central Jutland are part of Central Denmark Region.
The region is a public institution with three main tasks within welfare and regional development:
- Health and hospitals
- Specialised offers to socially marginalised groups and disabled
- Political driving force for growth through regional development
The Central Denmark Region has approximately 26,100 full-time employees and a budget of DKK 30 billions.
The largest part of the budget is spent on health.
The region is governed by 41 directly elected politicians.
The Central Denmark Region has 10 hospitals consolidated into five hospital units. Each unit has its own management and administration.